Deep knowledge on 
 small-molecule drugs and 
 the 100,000 global patents 
 covering them 

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

How are People Using DrugPatentWatch?

DrugPatentWatch Ultimate Plan Preview

Details for Generic Name: paclitaxel

« Back to Dashboard
Paclitaxel is the generic ingredient in three branded drugs marketed by Pliva Lachema, Actavis Totowa, Hospira, Accord Hlthcare, Mylan Labs Ltd, Abraxis Bioscience, Hq Spclt Pharma, Sandoz Inc, Fresenius Kabi Oncol, Mylan, Teva Pharms, Eurohlth Intl Sarl, and Teva Pharms Usa, and is included in fourteen NDAs. There are ten patents protecting this compound. Additional information is available in the individual branded drug profile pages.

This ingredient has one hundred and ninety-six patent family members in twenty-six countries.

There are sixty-five drug master file entries for paclitaxel. Two suppliers are listed for this compound.

Summary for Generic Name: paclitaxel

Tradenames:3
Patents:10
Applicants:13
NDAs:14
Drug Master File Entries: see list65
Suppliers / Packaging: see list4

Pharmacology for Ingredient: paclitaxel

Drug ClassMicrotubule Inhibitor
Physiological EffectMicrotubule Inhibition

Clinical Trials for: paclitaxel

Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma
Status: Active, not recruiting Condition: Resectable Pancreatic Adenocarcinoma

A Phase I Trial of the Combination of AZD2014 and Weekly Paclitaxel.
Status: Recruiting Condition: Advanced Cancer

BKM120 + Carboplatin + Paclitaxel for Patients With Advanced Solid Tumors
Status: Active, not recruiting Condition: Solid Tumors

Open-label Phase 1b Study of ARQ 092 in Combination With Carboplatin Plus Paclitaxel
Status: Recruiting Condition: Ovarian Cancer; Endometrial Cancer; Cervical Cancer; Breast Cancer Triple Negative

A Randomized Study of Intraperitoneal tgDCC-E1 and Intravenous Paclitaxel in Women With Platinum-Resistant Ovarian Cancer
Status: Withdrawn Condition: Ovarian Cancer

PH I SRC Kinase, Dasatinib Combo Paclitaxel & Carboplatin in Pts w Ovarian, Peritoneal, & Tubal Cancer
Status: Completed Condition: Ovarian Cancer; Peritoneal Cancer; Fallopian Tube Cancer

Phase 1b/2 Study of U3-1287 in Combination With Trastuzumab Plus Paclitaxel in Newly Diagnosed Metastatic Breast Cancer (MBC)
Status: Active, not recruiting Condition: Metastatic Breast Cancer

Intraperitoneal tgDCC-E1 and Intravenous Paclitaxel in Women With Platinum-Resistant Ovarian Cancer
Status: Terminated Condition: Ovarian Cancer

Hepatic Arterial Infusion (HAI) of Abraxane
Status: Completed Condition: Liver Cancer; Advanced Cancers; Solid Tumors

Breast Cancer Treatment Using Weekly Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting
Status: Recruiting Condition: Breast Carcinoma

Dasatinib In Combination With Weekly Paclitaxel For Patients With Metastatic Breast Carcinoma CA 180 194
Status: Active, not recruiting Condition: Breast Cancer

Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 and Nab®-Paclitaxel Monotherapy as Second Line Treatment for Advanced Nonsquamous Non-small Cell Lung Cancer
Status: Recruiting Condition: Carcinoma, Non-Small-Cell Lung

Nab-paclitaxel in Combination With Gemcitabine in Fragile Patients With Advanced Pancreatic Cancer
Status: Recruiting Condition: Advanced Pancreatic Cancer

Schedules of Nab-Paclitaxel in Metastatic Breast Cancer
Status: Active, not recruiting Condition: Metastatic Breast Cancer.

Assessment Of Stromal Response To Nab-Paclitaxel In Combination With Gemcitabine In Pancreatic Cancer
Status: Completed Condition: Pancreatic Cancer

Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer
Status: Recruiting Condition: Breast Neoplasms; Pancreatic Neoplasms

Triple-Negative First-Line Study: Neoadjuvant Trial of Nab-Paclitaxel and MPDL3280A, a Pdl-1 Inhibitor in Patients With Triple Negative Breast Cancer
Status: Recruiting Condition: Breast Cancer

Dose Escalation and Pharmacokinetic Study of Paclitaxel Liposome Injection in Treating Patients With Advanced Solid Tumor After Failure From Conventional Treatments
Status: Recruiting Condition: Solid Tumors

Study of Vemurafenib, Carboplatin, and Paclitaxel
Status: Recruiting Condition: Advanced Cancers

A Study of Ramucirumab (IMC-1121B) and Paclitaxel in Participants With Solid Tumors
Status: Active, not recruiting Condition: Malignant Solid Tumor

Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer)
Status: Completed Condition: Brenner Tumor; Fallopian Tube Cancer; Ovarian Carcinosarcoma; Ovarian Clear Cell Cystadenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mixed Epithelial Carcinoma; Ovarian Mucinous Cystadenocarcinoma; Ovarian Serous Cystadenocarcinoma; Ovarian Undifferentiated Adenocarcinoma; Primary Peritoneal Cavity Cancer; Stage II Ovarian Epithelial Cancer; Stage III Ovarian Epithelial Cancer; Stage IV Ovarian Epithelial Cancer

Nab-paclitaxel, Gemcitabine, and Bevacizumab in Advanced Malignancies
Status: Recruiting Condition: Advanced Cancer

Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer
Status: Completed Condition: Chemotherapeutic Agent Toxicity; Neuropathy; Neurotoxicity Syndrome; Pain; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer

Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer
Status: Recruiting Condition: Breast Cancer; Breast Carcinoma; Breast Tumors; Malignant Neoplasm of Breast

Investigating Safety, Tolerability and Efficacy of AZD5363 When Combined With Paclitaxel in Breast Cancer Patients
Status: Recruiting Condition: Advanced or Metastatic Breast Cancer,; ER+ve Advanced or Metastatic Breast Cancer.

Study of Concurrent Paclitaxel and Radiation: Correlation of Tumor Profiles With Pathologic Response
Status: Active, not recruiting Condition: Breast Cancer

PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Subjects With Stage IV Untreated Pancreatic Cancer
Status: Recruiting Condition: Metastatic Pancreatic Cancer

Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto)
Status: Active, not recruiting Condition: Tubular Breast Cancer Stage II; Mucinous Breast Cancer Stage II; Breast Cancer Female NOS; Invasive Ductal Breast Cancer; Tubular Breast Cancer Stage III; HER-2 Positive Breast Cancer; Inflammatory Breast Cancer Stage IV; Inflammatory Breast Cancer

Bioequivalence Study of IG-001 Versus Nab-paclitaxel in Metastatic or Locally Recurrent Breast Cancer
Status: Active, not recruiting Condition: Metastatic Breast Cancer; Locally Recurrent Breast Cancer

Gleevec/Taxol for Patients With Uterine Papillary Serous Carcinoma
Status: Completed Condition: Uterine Cancer

Hepatic Arterial Infusion of Nab-Paclitaxel in Patients With Metastatic Melanoma in the Liver
Status: Completed Condition: Melanoma; Liver Metastasis

Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)
Status: Active, not recruiting Condition: Squamous Cell Cancer; Head and Neck Cancer

A Study of BIIB022 in Combination With Paclitaxel and Carboplatin in Subjects With Non-Small Cell Lung Cancer
Status: Completed Condition: Non-Small Cell Lung Cancer

F16IL2 Plus Paclitaxel in Metastatic Merkel Cell Carcinoma
Status: Recruiting Condition: Merkel Cell Carcinoma

Women's Triple-Negative First-Line Study: A Phase II Trial of Panitumumab, Carboplatin and Paclitaxel (PaCT) in Patients With Localized Triple-Negative Breast Cancer (TNBC) With Tumors Predicted Insensitive to Standard Neoadjuvant Chemotherapy
Status: Not yet recruiting Condition: Breast Cancer

Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer
Status: Completed Condition: Metastatic Breast Cancer

Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
Status: Completed Condition: Brenner Tumor; Fallopian Tube Cancer; Ovarian Clear Cell Cystadenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mixed Epithelial Carcinoma; Ovarian Mucinous Cystadenocarcinoma; Ovarian Serous Cystadenocarcinoma; Ovarian Undifferentiated Adenocarcinoma; Primary Peritoneal Cavity Cancer; Stage II Ovarian Epithelial Cancer; Stage III Ovarian Epithelial Cancer; Stage IV Ovarian Epithelial Cancer

Paclitaxel-Carboplatin-Bevacizumab +/- Nitroglycerin in Metastatic Non-Squamous-Non-Small Cell Lung Cancer
Status: Recruiting Condition: Non Small Cell Lung Cancer

Study of Afuresertib Combined With Paclitaxel in Gastric Cancer
Status: Recruiting Condition: Cancer

Trial to Evaluate Paclitaxel Plus RAD001 in Urothelial Carcinoma
Status: Terminated Condition: Bladder Cancer

Lenalidomide and Paclitaxel in Prostate Cancer
Status: Terminated Condition: Prostate Cancer

M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
Status: Recruiting Condition: Metastatic Pancreatic Cancer

Topical Cryotherapy in Reducing Pain in Patients With Chemotherapy Induced Peripheral Neuropathy or Paclitaxel Induced Acute Pain Syndrome
Status: Recruiting Condition: Acute Pain; Breast Carcinoma; Neuropathic Pain; Peripheral Neuropathy

Phase IB/II Trial of LDE225 and Paclitaxel in Recurrent Ovarian Cancer
Status: Recruiting Condition: Recurrent Ovarian Cancer

Phase I Dose Escalation of Oral BAY1161909 in Combination With Intravenous Paclitaxel
Status: Recruiting Condition: Medical Oncology

Phase II Neoadjuvant Chemotheraphy (Gemcitabine and Nab-Paclitaxel vs. mFOLFIRINOX) and Sterotatic Body Radiation Therapy for Borderline Resectable Pancreatic Cancer
Status: Recruiting Condition: Borderline Resectable Pancreatic Cancer

Gemcitabine, Cisplatin, and Abraxane in Advanced Biliary Cancers
Status: Recruiting Condition: Biliary Tract Cancer

Phase I/II Trial of the Combination of Lenalidomide (Revlimid) and Nab-paclitaxel (Abraxane) in the Treatment of Relapsed/Refractory Multiple Myeloma
Status: Terminated Condition: Relapsed or Refractory Multiple Myeloma

Combining Abraxane With Capecitabine and Radiation Therapy for Consolidation of Treatment Following Induction Chemotherapy for Locally Advanced Pancreatic Cancer
Status: Recruiting Condition: Pancreatic Cancer

Paclitaxel Administered by HAI to Patients With Advanced Cancer and Dominant Liver Involvement
Status: Completed Condition: Advanced Cancer

Fosbretabulin or Placebo in Combination With Carboplatin/Paclitaxel in Anaplastic Thyroid Cancer
Status: Withdrawn Condition: Anaplastic Thyroid Cancer

HSP90 Inhibitor AT13387 and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer
Status: Recruiting Condition: Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Recurrent Breast Carcinoma; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer; Triple-Negative Breast Carcinoma

MK2206 and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Metastatic Breast Cancer
Status: Active, not recruiting Condition: Adult Solid Neoplasm; Recurrent Breast Carcinoma; Stage IV Breast Cancer

Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal Cancer
Status: Recruiting Condition: Gastroesophageal Cancer

Intraperitoneal Paclitaxel and Carboplatin With IV Avastin Therapy in Patients With Carcinomas of Mullerian Origin
Status: Active, not recruiting Condition: Ovarian Cancer; Peritoneal Cancer; Fallopian Tube Cancer

Efficacity of Weekly Paclitaxel in Association or Not With Bevacizumab in Metastatic or Locally Advanced Angiosarcomas
Status: Active, not recruiting Condition: Angiosarcoma; Paclitaxel

Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung Cancer
Status: Recruiting Condition: Squamous Cell Carcinoma, Non-Small-Cell Lung

Metformin Plus Paclitaxel for Metastatic or Recurrent Head and Neck Cancer
Status: Terminated Condition: Head and Neck Neoplasms; Squamous Cell Carcinoma

Nab-paclitaxel Plus S-1 in Patients With Advanced Pancreatic Cancer
Status: Recruiting Condition: Advanced Pancreatic Cancer

Phase I/Ib Study of Paclitaxel in Combination With VS-6063 in Patients With Advanced Ovarian Cancer
Status: Active, not recruiting Condition: Ovarian Cancer

Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)
Status: Active, not recruiting Condition: Breast Tumor; Breast Cancer; Cancer of the Breast; Estrogen Receptor- Negative Breast Cancer; HER2- Negative Breast Cancer; Progesterone Receptor- Negative Breast Cancer; Recurrent Breast Cancer; Stage IV Breast Cancer; Triple-negative Breast Cancer; Triple-negative Metastatic Breast Cancer; Metastatic Breast Cancer

Nab-paclitaxel Plus Gemcitabine in Chinese Patients With Advanced Pancreatic Cancer
Status: Recruiting Condition: Advanced Pancreatic Cancer

A Phase I/II Study of Nab-Paclitaxel, or Paclitaxel, Plus Carboplatin With Concurrent Radiation Therapy Followed by Consolidation in Patients With Favorable Prognosis Inoperable Stage IIIA/B NSCLC
Status: Recruiting Condition: INOPERABLE STAGE IIIA/B NON-SMALL CELL LUNG CANCER

A Study of Paclitaxel/Carboplatin With or Without CDP791 in Patients With Lung Cancer
Status: Completed Condition: Carcinoma; Non-Squamous Non-Small-Cell Lung Cancer

Combination Treatment of S-1 With Paclitaxel in Advanced Esophageal Cancer
Status: Recruiting Condition: Esophageal Cancer

Carboplatin and Paclitaxel Combined With Cetuximab and/or IMC-A12 in Patients With Advanced Non-Small Cell Lung Cancer
Status: Completed Condition: Recurrent Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer

Dasatinib, Bevacizumab, Paclitaxel in Patients With Advanced Malignancies
Status: Active, not recruiting Condition: Advanced Cancer

Prevention of Paclitaxel Neuropathy With Cryotherapy
Status: Active, not recruiting Condition: Breast Cancer

Cisplatin vs Paclitaxel for Triple Neg
Status: Recruiting Condition: Triple Negative Breast Cancer

LDE225 and Paclitaxel in Solid Tumors
Status: Active, not recruiting Condition: Solid Tumor; Ovarian Cancer

MLN8237 in Patients With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer
Status: Active, not recruiting Condition: Ovarian Carcinoma; Fallopian Tube Cancer; Peritoneal Cancer; Breast Carcinoma

Selinexor, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Pancreatic Cancer
Status: Recruiting Condition: Acinar Cell Adenocarcinoma of the Pancreas; Duct Cell Adenocarcinoma of the Pancreas; Stage IV Pancreatic Cancer

Combination Therapy of F16IL2 and Paclitaxel in Solid Tumour Patients
Status: Recruiting Condition: Solid Tumour,; Breast Cancer,; Metastatic Melanoma,; Non-small Cell Lung Cancer (NSCLC),

To Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors
Status: Recruiting Condition: Neuroblastoma;; Rhabdomyosarcoma;; Ewing's Sarcoma;; Ewing's Tumor;; Sarcoma, Ewing's;; Sarcomas, Epitheliod;; Sarcoma, Soft Tissue;; Sarcoma, Spindle Cell;; Melanoma;; Malignant Melanoma;; Clinical Oncology;; Oncology, Medical;; Pediatrics, Osteosarcoma;; Osteogenic Sarcoma;; Osteosarcoma Tumor;; Sarcoma, Osteogenic;; Tumors;; Cancer;; Neoplasia;; Neoplasm;; Histiocytoma;; Fibrosarcoma;; Dermatofibrosarcoma

Role of Tirofiban and the Paclitaxel Eluting Stent in Postfibrinolysis Angioplasty
Status: Completed Condition: Myocardial Infarction

The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer
Status: Active, not recruiting Condition: Metastatic Breast Cancer

Phase 2 Nab® -Paclitaxel (Abraxane®) Plus Gemcitabine in Subjects With Locally Advanced Pancreatic Cancer (LAPC)
Status: Recruiting Condition: Pancreatic Neoplasms

Phase I & II Trial of Intravesicular Abraxane for Treatment-refractory Bladder Cancer
Status: Recruiting Condition: Bladder Cancer

A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer
Status: Recruiting Condition: Metastatic Breast Cancer

A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation
Status: Completed Condition: Breast Cancer

Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)
Status: Recruiting Condition: Pancreatic Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Endocrine Gland Neoplasms; Pancreatic Diseases; Digestive System Diseases; Endocrine System Diseases; Gemcitabine; Antimetabolites, Antineoplastic

Lapatinib in Combination With Weekly Paclitaxel in Patients With ErbB2 Amplified Advanced Gastric Cancer
Status: Completed Condition: Neoplasms, Gastrointestinal Tract

Study With Pazopanib and Weekly Paclitaxel in Penile Carcinoma (PAZOPEN-SOGUG)
Status: Recruiting Condition: Penile Squamous Cell Carcinoma Stage IV

Treatment With Nab-paclitaxel in Cutaneous SCC
Status: Not yet recruiting Condition: Cutaneous Squamous Cell Carcinoma

Phase Ib Study of Olaparib Plus Weekly Carboplatin and Paclitaxel in Relapsed Ovarian Cancer
Status: Active, not recruiting Condition: Stage III Ovarian Cancer; Stage IV Ovarian Cancer; Uterine Cancer

First-line Treatment of Weekly Paclitaxel With Carboplatin and Bevacizumab in Ovarian Cancer
Status: Active, not recruiting Condition: Epithelial Ovarian Cancer; Primary Peritoneal Carcinoma; Fallopian Tube Cancer

Paclitaxel, Bevacizumab and Pemetrexed in Patients With Untreated, Advanced Non-Small Cell Lung Cancer Using Web-Based Data Collection, Patient Self-Reporting of Adverse Effects and Automated Response Assessment
Status: Completed Condition: Lung Cancer

Ph 1 Study of VS-4718, a FAK Inhibitor, in Combination With Nab-paclitaxel and Gemcitabine in Advanced Cancer Subjects
Status: Recruiting Condition: Pancreatic Cancer

Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel in Squamous Cell Carcinoma of Esophagus
Status: Withdrawn Condition: Squamous Cell Carcinoma of Esophagus

Drug-Eluting Balloon Catheters and the Treatment of Peripheral Arterial Occlusive Disease
Status: Completed Condition: Peripheral Arterial Disease; Stenotic Femoro-popliteal Arteries; Occluded Femoro-popliteal Arteries; Atherosclerosis

Dose-Escalation Study Of Palbociclib + Nab-Paclitaxel In mPDAC
Status: Recruiting Condition: Metastatic Pancreatic Ductal Adenocarcinoma

Study of 5-fluorouracil (5-FU), Nab-paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin in Patients With Metastatic Pancreatic Cancer
Status: Recruiting Condition: Metastatic Pancreas Adenocarcinoma

Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer
Status: Recruiting Condition: Thyroid Gland Undifferentiated (Anaplastic) Carcinoma

Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
Status: Suspended Condition: Bronchioloalveolar Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Squamous Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer; Stage IIIB Non-Small Cell Lung Cancer

Pharmacokinetic and Safety Study of Nab®-Paclitaxel (ABI-007) Plus Gemcitabine in Subjects With Advanced Pancreatic Cancer Who Have Cholestatic Hyperbilirubinemia
Status: Active, not recruiting Condition: Pancreatic Neoplasms; Cholestasis

Phase II Trial of Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Cholangiocarcinoma
Status: Recruiting Condition: Cholangiocarcinoma

Phase I/II AZD8931/Paclitaxel in Treatment of Advanced Solid Tumours (Phase I) and Advanced Breast Cancer (Phase II)
Status: Completed Condition: Neoplasms; Breast Neoplasms; Breast Cancer

Endoscopic Ultrasound (EUS) Guided Ethanol With Paclitaxel Ablation for Pancreatic Mucinous Cystic Neoplasm
Status: Recruiting Condition: Mucinous Cystic Tumor With Moderate Dysplasia; Mucinous Cystadenoma of Pancreas; Mucinous Cystadenocarcinoma of Pancreas; Benign Neoplasm of Pancreas

Safety, Feasibility and Effect of TTFields Concomitant With Weekly Paclitaxel in Recurrent Ovarian Carcinoma
Status: Recruiting Condition: Ovarian Carcinoma

Single Arm on the Tolerability of Weekly Nab-paclitaxel
Status: Recruiting Condition: Non Small Cell Lung Cancer (NSCLC)

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mylan
PACLITAXEL
paclitaxel
INJECTABLE;INJECTION075278-001Jan 25, 2002DISCNNo<disabled><disabled>
Abraxis Bioscience
ABRAXANE
paclitaxel
FOR SUSPENSION;IV (INFUSION)021660-001Jan 7, 2005RXYes8,138,229<disabled>Y <disabled>
Abraxis Bioscience
ABRAXANE
paclitaxel
FOR SUSPENSION;IV (INFUSION)021660-001Jan 7, 2005RXYesRE41884<disabled> <disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: paclitaxel

These historical archives are available as an add-on to one-year subscriptions

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Hq Spclt Pharma
TAXOL
paclitaxel
INJECTABLE;INJECTION020262-001Dec 29, 19926,096,331<disabled>
Abraxis Bioscience
ABRAXANE
paclitaxel
FOR SUSPENSION;IV (INFUSION)021660-001Jan 7, 20055,439,686<disabled>
Hq Spclt Pharma
TAXOL
paclitaxel
INJECTABLE;INJECTION020262-001Dec 29, 19926,150,398<disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: paclitaxel

Country Document Number Publication Date
Australia2007317859May 15, 2008
European Patent Office2301531Jul 27, 2011
World Intellectual Property Organization (WIPO)9900113Jan 07, 1999
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2016 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc